How Soon Could President Biden Enable Generic Competition to Xtandi? Very Quickly, If There Is the Will.
The Biden Administration could take a number of legal measures to ensure the timely entrance of a generic competitor to Xtandi.
Bayh-Dole Act
-
Read more: How Soon Could President Biden Enable Generic Competition to Xtandi? Very Quickly, If There Is the Will. -
Read more: We All Stand to Benefit from Biden’s $2 Billion Bet on the Bioeconomy We All Stand to Benefit from Biden’s $2 Billion Bet on the Bioeconomy
Biden’s new initiative takes an expansive view of the roles of biotechnology and biomanufacturing in the United States economy.
-
Read more: A Response to ‘Another Legislative Attempt to Revive Gene Patenting’ A Response to ‘Another Legislative Attempt to Revive Gene Patenting’
Including purified and isolated materials as eligible subject matter under 35 U.S.C. ยงย 101 can benefit patients, researchers, and innovation.
-
Read more: Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIH Funding in Key Gleevec Patent Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIH Funding in Key Gleevec Patent
By James Love This is a story about U.S. patent number 6,958,335, and how it took more than 18 years for Novartis to acknowledge National Institutes of Health (NIH) funding in a key patent for Gleevec, allowing Novartis to shape the narrative regarding its role in the development of Gleevec, and also to avoid demands…
